Luis E. Raez: Sometimes new agents don’t have a better OS but they provide benefits

Luis E. Raez, Medical Director at Memorial Cancer Institute, shared a post by Stephen Liu on X:

“Sometimes new agents don’t have a better OS but at least if they provide a benefit like PFS and the toxicity profile it’s better, those are good benefits for our patients instead of using a 25 year old agent!

Let’s see the data.” .

Quoting Stephen Liu’s post:

“TROPION-Lung01 press release: Trop2 ADC datopotamab deruxtecan vs docetaxel in previously treated NSCLC, previously met PFS endpoint, does not meet OS endpoint but shows clinically meaningful OS benefit in nonsquamous subset.

Need to see full dataset.”

Source: Luis E. Raez/X and Stephen V Liu/X

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives.

Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.